Trial Profile
An Early Access Program for Durvalumab and Tremelimumab as First Line Treatment for Patients With Unresectable Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Liver cancer
- Focus Expanded access; Therapeutic Use
- Sponsors AstraZeneca
- 05 Dec 2022 Status changed from recruiting to completed.
- 03 May 2022 New trial record